|
A Phase 3 Randomized Study of Lonafarnib in Combination With Paclitaxel and Carboplatin vs. Placebo in Combination with Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, trips or professional assistance with a real medical doctor. We aren't docs. Always confer with your doctor about A Phase 3 Randomized Study of Lonafarnib in Combination With Paclitaxel and Carboplatin vs. Placebo in Combination with Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. A Phase 3 Randomized Study of Lonafarnib in Combination With Paclitaxel and Carboplatin vs. Placebo in Combination with Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer Clinical research trials and A Phase 3 Randomized Study of Lonafarnib in Combination With Paclitaxel and Carboplatin vs. Placebo in Combination with Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer health trials happen in many of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectualness of new does drugs. The intention of the studies / projects is to figure out particular human healthcare questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to detect cures for all forms of circumstances, like A Phase 3 Randomized Study of Lonafarnib in Combination With Paclitaxel and Carboplatin vs. Placebo in Combination with Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer. A Phase 3 Randomized Study of Lonafarnib in Combination With Paclitaxel and Carboplatin vs. Placebo in Combination with Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment options before they are available to the general public. Most times the subjects get treatment for free of charge, and occasionally they are paid for their time. Occasionally there is a cost for a A Phase 3 Randomized Study of Lonafarnib in Combination With Paclitaxel and Carboplatin vs. Placebo in Combination with Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer clinical trial. Subjects frequently get the best healthcare possible for their A Phase 3 Randomized Study of Lonafarnib in Combination With Paclitaxel and Carboplatin vs. Placebo in Combination with Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer condition. Hazards are a reality, however, and could include more or frequent mD visits, health risks (possibly life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Phase 3 Randomized Study of Lonafarnib in Combination With Paclitaxel and Carboplatin vs. Placebo in Combination with Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer A Phase 3 Randomized Study of Lonafarnib in Combination With Paclitaxel and Carboplatin vs. Placebo in Combination with Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer
A Phase 3 Randomized Study of Lonafarnib in Combination With Paclitaxel and Carboplatin vs. Placebo in Combination with Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer
For Condition: Metastases, Neoplasm,Carcinoma, Non-Small-Cell Lung
Status: Terminated
Sponsor(s): Schering-Plough ,
Synopsis: The purpose of this study is to determine the overall survival of patients diagnosed with Stage 3b or 4 non-small cell lung cancer treated with an oral Farnesyl Protein Transferase Inhibitor (Lonafarnib/SCH 66336) in combination with paclitaxel and carboplatin with that of patients treated with placebo in combination with paclitaxel and carboplatin.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Single Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Male or female - Histologically or cytologically 3b or 4 (metastatic) non-small cell lung cancer. Patients must meet any subcriteria as detailed in the protocol. - Age greater than or equal to 18 years old - ECOG performance status of 0 to 1 - Prior diagnosis of brain metastases from NSCLC eligible provided that the brain metastases have been adequately treated, patient is neurologically stable and no new or progressive brain metastases identified. - Meets protocol requirements for specified laboratory values - Written informed consent - Appropriate use of effective contraception if of childbearing potential - Prior basal cell carcinoma or carcinoma in-situ of the cervix are eligible provided they have been treated with no evidence of disease Exclusion Criteria: - Prior chemotherapy for any stage of NSCLC - Prior surgery or radiation therapy within the last 2 weeks or incomplete recovery from prior procedures or therapy - Concurrent treatment or treatment within the last 2 years for any other malignancy - Grade 2 or greater nausea or Grade 1 or greater vomiting (despite antiemetic medication) - Medical conditions that would interfere with taking oral medications - Patients with bone metastases as the only site of disease - Pregnant or nursing women - Known HIV positivity or AIDS-related illness - Patients with significant QTc prolongation at baseline
Total Enrollment: 800
Location and Contact Information:
Glasgrow Royal Infirmary - St. Mungo Institute
Glasgow, , G4-OSF
United Kingdom
Helsingin Yliopistollinen Keskussairaala
Helsinki, ,
Finland
Clinique Victor Hugo
Le Mans, , 72015
France
The West Clinic (NCCN)
Memphis, Tennessee, 38120
United States
Hopital Nacionale Guillermo Almenara
Lima, , 13
Peru
Northwest Medical Specialities
Tacoma, Washington, 98405
United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111
United States
Highlands Oncology (Private)
Bentonville, Arkansas, 72712
United States
Ospedale Niguarda-Ca Granda
Milano, ,
Italy
Lungenklinik Hemer
Hemer, , 58675
Germany
Rocky Mountain Cancer Centers LLP (Private) US Oncology
Colorado Springs, Colorado, 80218
United States
University of Arizona (Arizona Cancer Ctr)
Tucson, Arizona, 85724
United States
Pittsburgh Cancer Research Network
Pittsburgh, Pennsylvania, 15232-1305
United States
New Mexico Cancer Care
Santa Fe, New Mexico, 87505
United States
Hematology Oncology Clinic
Baton Rouge, Louisiana, 70808
United States
Genesis Health Care System
Zanesville, Ohio,
United States
Centro Medico Nacional De Occidente/Hospital Especialidades
Guadalajara, Jalisco, 4430
Mexico
Masonic Cancer Center University of Minnesota
Minneapolis, Minnesota, 55455
United States
Grady Memorial Hospital (affialited with Emory Univ.)
Atlanta, Georgia, 30303-0001
United States
Providence Regional Cancer Center
Portland, Oregon, 97213
United States
James Graham Brown Cancer Center
Louisville, Kentucky,
United States
Instituto De Cancerologia Clinica Las Americas
Medllin, ,
Colombia
St. Clarapital
Basel, , 4016
Switzerland
Veteran Administrative Medical Center
Reno, Nevada, 89502
United States
Odyssey Research
Fargo, North Dakota, 58104
United States
Mary Bird Perkins Center
Baton Rouge, Louisiana, 70809
United States
Lucille Parker Markey Cancer Ctr (Univ. of Kentucky Med. Ctr,)
Lexington, Kentucky, 40536
United States
Louisville Oncology
Louisville, Kentucky, 40202
United States
Southern Nevada Center
Las Vegas, Nevada, 89106
United States
Odyssey Research
Minot, North Dakota, 58701
United States
Krankenhaus Grosshansdorf
Grosshandsdorf, , 22927
Germany
Hopsital Charles-Lemoyne Greenfield Park
Greenfield Park, ,
Canada
Odyssey Research
Bismark, North Dakota, 58501
United States
Hoptial Laval
Quebec, , G1V4G5
Canada
University of Chicago
Chicago, Illinois, 60637-1470
United States
Istituto Nazional Per La Ricerca
Genova, , 16132
Italy
Hematology & Oncology Specialists
New Orleans, Louisiana, 70115
United States
Hospital Edgardo Rebagliati Martins
Lima, , 11
Peru
Clinique Victor Hugo
Le Mans, ,
France
Centro Medico Imbanaco
Cali, ,
Colombia
Klinikum der Johnannes Gutenberg - Univ. Mainz
Maniz, , 55131
Germany
Green Mountain Oncology Group
Bennington, Vermont, 05201
United States
New Mexico Oncology Hematology Consultants
Albuquerque, New Mexico, 87109
United States
Instituto de Oncologia Carlos Ardila Lule
Bogota, ,
Colombia
Arlington-Fairfax Hematology & Oncology Assoc.
Arlington, Virginia, 22554
United States
Helsingin Yliopistollinen Keskussairaala
Helsinki, ,
Finland
St. Barnabas Medical Center
Livingston, New Jersey, 07039
United States
Ospedale Bellaria
Bologna, , 40139
Italy
Hospital Universitario Virgen de la Victoria
Malaga, ,
Spain
University of Colorado Cancer Center
Denver, Colorado, 80010
United States
Arlington Cancer Center
Arlington, Texas, 76012
United States
Royal Marsden Hospital (Surrey)
Sutton, , SM2-5PT
United Kingdom
Instituto Clinico Humanitas
Rozzano, , 20089
Italy
Hospital Clinico San Carlos
Madrid, , 28040
Spain
Peachtree Hematology/Oncology
Atlanta, Georgia, 30309
United States
Florida Hospital Cancer Institute (Walt Disney Med.)
Orlando, Florida, 32804
United States
Leo Jenking Cancer Center (East Carolina University)
Greenville, North Carolina, 27858
United States
Louisiana Oncology Associates (Private)
Lafayette, Louisiana, 70506
United States
Emory University (Winship Cancer Ctr.)
Atlanta, Georgia, 30332
United States
Pinnacle Health Regional Cancer Center
Harrisburg, Pennsylvania,
United States
Western Maryland Health System
Cumberland, Maryland, 21502
United States
Fundacion Arturo Lopez Perez
Santiago, ,
Chile
Genesis Health Care Systems Cancer Serv.
Zanesville, Ohio, 43701
United States
Instituto Nacional de Enfermedades Neoplasicas
Lima, ,
Peru
Baptist Regional Cancer Center
Knoxville, Tennessee, 37920
United States
Hospital Universitario - Virgen Del La Victoria
Malaga, , 29010
Spain
Maine Center for Cancer Med. and Blood Disorders
Scarborough, Maine, 04074
United States
Centre Hospitalier de Belfort-Montbeliard
Belfort, , 90016
France
Clinica Santa Maria
Santiago, ,
Chile
Hematology-Oncology of Indiana
Indianapolis, Indiana, 46260
United States
Rhode Island Hospital
Providence, Rhode Island, 02903
United States
Southwest Regional Cancer
Austin, Texas, 78705
United States
Queens Medical Center (Hospital)
Oahu, Hawaii, 96813
United States
Odyssey Research
Bismark, North Dakota, 58501
United States
Georgia Cancer Specialists
Tucker, Georgia,
United States
Cancer Care of WNC
Asheville, North Carolina, 28801
United States
Associates in Hematology - Oncology, PC
Upland, Pennsylvania, 19013
United States
MD Anderson Cancer Center (affiliated with Orlando Regional Health Care
Houston, Texas, 77030-4009
United States
Southern Oncology Research
Greenville, North Carolina, 27834
United States
Kansas City Oncology and Hematology Group
Lenexa, Kansas, 64111
United States
Duke Cancer Research
Durham, North Carolina,
United States
Northern Virginia Oncology Group
Fairfax, Virginia, 22031
United States
Jane Graham Brown Cancer Center
Louisville, Kentucky, 40202
United States
The Lung Center at Mercy Hosptial
Charlotte, North Carolina, 28207
United States
Little Rock Hematology/Oncology Associates
Little Rock, Arkansas,
United States
Hospital IESS - Carlos Andrade Marin
Pichincha, ,
Ecuador
Krankenhaus, Staedtisches Krankenhaus
Halle, , 6120
Germany
Albert Einstein Medical Center
Philadelphia, Pennsylvania, 19141
United States
University of Cape Town
Cape Town, , 7925
South Africa
South Texas Oncology
San Antonio, Texas,
United States
Peninsula Regional Medical Center (Hospital)
Salisbury, Maryland,
United States
Klinikum rechts der Isar der Technischen - Univ. Muenchen
Muenchen, , 81675
Germany
Inst. Nacional de Enfermedades
Surquillo, Lima, 34
Peru
Hopital St Joseph
Marseille, ,
France
National Cancer Centre
Singapore, , 169610
Singapore
Hospital Ramon y Cajal
Madrid, , 28034
Spain
Huntsman Cancer Institute
Salt Lake City, Utah, 84112-5550
United States
Leicester Royal Infirmary
Leicester, , LE-1-5WW
United Kingdom
Hospices Civils de Lyon
Pierre-Benite, , 69495
France
Lungenklinik Heckeshorn
Berlin, , D14109
Germany
Additional Information:
Study ID Numbers: P01901;
Study Start Date: November 2002
Record last reviewed: July 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00050336
Other Metastases, Neoplasm Studies:
1. Iressa Expanded Access Program (EAP)
2. Magnetic-Targeted Doxorubicin in Treating Patients with Cancer Metastatic to the Liver
3. Phase I-II study to evaluate safety, efficacy and pharmacokinetic interactions between capecitabine (XELODA) and exisulind (APTOSYN) in patients with metastatic breast cancer.
4. Study of Temozolomide in the Treatment of Brain Metastasis from Non-small-cell Lung Cancer
5. A Phase II Clinical Trial of ABI-007, Administered Weekly in Taxol Resistant Patients with Metastatic Breast Cancer
Related Studies:
Other Metastases, Neoplasm Clinical Trials
Other Clinical Trials
Other Leicester Clinical Trials
A Phase 3 Randomized Study of Lonafarnib in Combination With Paclitaxel and Carboplatin vs. Placebo in Combination with Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer
|
|
|
|
|
|
|
|